ENPP2 and pulmonary fibrosis: Finally, during the last decade, many research campaigns have focused on the development of drugs targeting the ATX-LPA axis [ATX inhibitors: Ziritaxestat® (GLPG1690), BBT-877; LPAR antagonists: SAR100842, BMS 986020) in interstitial pulmonary fibrosis and systemic sclerosis (NCT03711162, NCT03830125 (290, 291)].